2894-68-0 Usage
Description
Diclazepam, also known as 2-chlorodiazepam and chlorodiazepam, is a benzodiazepine derivative and a diazepam analogue. It was first synthesized by Leo Sternbach and his team at Hoffman-La Roche in 1960 but was not pursued as a pharmaceutical product. Diclazepam has not been formally studied for dosage, efficacy, or safety in humans, but it is known to have similar effects to flubromazepam and diazepam in animals. These effects include acting as an anticonvulsant, anxiolytic, sedative, hypnotic, amnesiac, and skeletal muscle relaxant. It may also cause adverse effects such as drowsiness and short-term memory impairment.
Uses
Used in Pharmaceutical Industry:
Diclazepam is used as a potential therapeutic agent for various conditions due to its multiple pharmacological effects. In animals, it has demonstrated anticonvulsant, anxiolytic, sedative, hypnotic, amnesiac, and skeletal muscle relaxant properties, making it a candidate for the treatment of seizures, anxiety, insomnia, and muscle spasms.
Used in Research and Development:
Diclazepam serves as a valuable compound in the research and development of new pharmaceuticals. Its structural similarity to diazepam and its known effects in animals make it a useful reference point for the development of novel benzodiazepine-based drugs with improved efficacy and safety profiles.
Used in Metabolism Studies:
The metabolism of Diclazepam, which involves N-demethylation and hydroxylation by cytochrome P450 enzymes, provides valuable insights into the metabolic pathways of benzodiazepines. This information can be applied to the design of drugs with more favorable pharmacokinetic properties and to understand the potential for drug-drug interactions involving benzodiazepines.
Used in Toxicology and Forensic Analysis:
The detection of Diclazepam and its metabolites, such as delorazepam, lormetazepam, and lorazepam, in biological samples can be useful in toxicology and forensic analysis. The elimination half-life and the duration for which these metabolites can be detected in the body can provide important information about the timing and extent of drug exposure.
Check Digit Verification of cas no
The CAS Registry Mumber 2894-68-0 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,8,9 and 4 respectively; the second part has 2 digits, 6 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 2894-68:
(6*2)+(5*8)+(4*9)+(3*4)+(2*6)+(1*8)=120
120 % 10 = 0
So 2894-68-0 is a valid CAS Registry Number.
InChI:InChI=1/C16H12Cl2N2O/c1-20-14-7-6-10(17)8-12(14)16(19-9-15(20)21)11-4-2-3-5-13(11)18/h2-8H,9H2,1H3
2894-68-0Relevant articles and documents
Structure-Activity Relationship Studies of Retro-1 Analogues against Shiga Toxin
Abdelkafi, Hajer,Michau, Aurélien,Pons, Valérie,Ngadjeua, Flora,Clerget, Alexandra,Ait Ouarab, Lilia,Buisson, David-Alexandre,Montoir, David,Caramelle, Lucie,Gillet, Daniel,Barbier, Julien,Cintrat, Jean-Christophe
, p. 8114 - 8133 (2020/09/21)
High-throughput screening has shown that Retro-1 inhibits ricin and Shiga toxins by diminishing their intracellular trafficking via the retrograde route, from early endosomes to the Golgi apparatus. To improve the activity of Retro-1, a structure-activity relationship (SAR) study was undertaken and yielded an analogue with a roughly 70-fold better half-maximal effective concentration (EC50) against Shiga toxin cytotoxicity measured in a cell protein synthesis assay.
Method for inhibiting the proliferation of tumor cells
-
, (2008/06/13)
A method of inhibiting the proliferation of tumor cells is disclosed which comprises the treatment of such tumor cells with a benzodiazepine having a selective affinity to bind peripheral binding sites on the tumor cell in order to induce non-proliferation of said tumor cells.
This product is a nationally controlled contraband, and the Lookchem platform doesn't provide relevant sales information.